Pembrolizumab

In this article, we will discuss about Pembrolizumab (Dosage). So, let’s get started.

Dosage

Melanoma: 200 mg every 3 weeks or 400 mg every 6 weeks.

Non-Small Cell Lung Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.

Small Cell Lung Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.

Head and Neck Squamous Cell Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.

Classical Hodgkin Lymphoma or Primary Mediastinal Large B-Cell Lymphoma: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.

Urothelial Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks.

Microsatellite Instability-High or Microsatellite Instability-High or Mismatch Repair Deficient Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for
pediatrics.

Microsatellite Instability-High or Microsatellite Instability-High or Mismatch Repair Deficient Cancer Colorectal Cancer: 200 mg every 3 weeks or 400 mg every
6 weeks.

Gastric Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.

Esophageal Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.

Cervical Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.

Hepatocellular Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks.

Merkel Cell Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.

Renal Cell Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks with axitinib 5 mg orally twice daily.

Endometrial Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks with lenvatinib 20 mg orally once daily for tumors that are not MSI-H or DMMR.

Tumor Mutational Burden-High Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.

Cutaneous Squamous Cell Carcinoma: 200 mg every weeks or 400 mg every 6 weeks.

Triple Negative Breast Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks. Administer Pembrolizumab (KEYTRUDA®) as an intravenous infusion over 30 minutes.

Adverse Reactions

Most common adverse reactions (reported in ≥20% of patients) were:

Pembrolizumab (KEYTRUDA®) as a single agent fatigue, musculoskeletal pain, decreased appetite, pruritus. diarrhea, nausea, rash, pyrexia, cough, dyspnea, constipation, pain, and abdominal pain.

Pembrolizumab (KEYTRUDA®) in combination with chemotherapy: fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, pyrexia, alopecia, peripheral neuropathy, mucosal inflammation, stomatitis, headache, and weight loss.

Pembrolizumab (KEYTRUDA®) in combination with axitinib: diarrhea,
fatigue, asthenia, hypertension, hepatotoxicity. hypothyroidism,
decreased appetite, palmar-plantar erythrodysesthesia, nausea,
stomatitis/mucosal inflammation, dysphonia, rash, cough, and
constipation.

Pembrolizumab (KEYTRUDA®) in combination with lenvatinib: fatigue, hypertension, musculoskeletal pain, diarrhea, decreased appetite, hypothyroidism, nausea, stomatitis, vomiting, weight loss, abdominal pain, headache. constipation, urinary tract infection, dysphonia, hemorrhagic events, hypomagnesemia, palmar-plantar
erythrodysesthesia, dyspnea, cough, and rash.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.